EGFR and neoplasm: We first performed analysis of serum-derived cfDNA by using the Therascreen Plasma RGQ kit, which detected the same EGFR activating mutation found in tumor tissue at baseline in 13 out of 29 patients, showing therefore a 44.8% sensitivity.